Objective To observe the clinical effect of sacubitril valsartan sodium tablets in the treatment of dilated cardiomyopathy.Methods A total of 62 patients with dilated cardiomyopathy were divided into a control group(31 cases,conventional medication)and an experimental group(31 cases,conventional medication+sacubitril valsartan sodium tablets)based on two-color ball random grouping method.Patients in both groups were compared in terms of clinical efficacy,incidence of adverse reactions,cardiac function index,plasma N-terminal pro-brain natriuretic peptide,plasma B-type natriuretic peptide,serological index and myocardial protein.Results After treatment,the left ventricular end-diastolic diameter and left ventricular end-systolic diameter in both groups were lower than those before treatment,and the left ventricular ejection fraction was higher than that before treatment(P<0.05).Compared with the control group[(62.55±2.45)mm,(56.51±3.44)mm,(54.31±2.31)%],the left ventricular end-diastolic diameter(55.15±2.42)mm and the left ventricular end-systolic diameter(48.17±3.48)mm were decreased in the experimental group after treatment,and the left ventricular ejection fraction(64.16±2.35)%)increased(P<0.05).After treatment,the plasma N-terminal pro-brain natriuretic peptide and B-type natriuretic peptide in both groups were decreased compared with those before treatment(P<0.05).Compared with the control group[(3354.69±131.49),(408.18±29.83)ng/L],plasma N-terminal pro-brain natriuretic peptide(2926.51±125.54)ng/L,and B-type natriuretic peptide(219.54±29.87)ng/L were significantly decreased in the experimental group after treatment(P<0.05).After treatment,the serum aldosterone,norepinephrine and angiotensin Ⅱ in both groups were decreased compared with those before treatment(P<0.05).Compared with the control group[(248.26±10.41)ng/L,(63.79±3.43)μg/L,(58.03±3.48)ng/L],the serum aldosterone(281.21±10.45)ng/L,norepinephrine(48.45±3.48)μg/L and angiotensin Ⅱ(51.36±3.42)ng/L were significantly decreased in the experimental group after treatment(P<0.05).After treatment,the troponin T and troponin I in both groups were lower than those before treatment(P<0.05).Compared with the control group[(0.41±0.09)and(0.53±0.09)μg/L],troponin T(0.28±0.06)μg/L and troponin I(0.33±0.07)μg/L were significantly decreased in the experimental group after treatment(P<0.05).The total effective rate of 100.00%in the experimental group was higher than 77.42%in the control group(P<0.05).There was little difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Sacubitril valsartan sodium tablets can effectively enhance the therapeutic effect of patients with dilated cardiomyopathy and has a high safety profile.
维普
万方数据
